Skip to main content

Table 5 Univariate Cox regression model of clinical parameters on disease specific survival in different EOC

From: Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers

Residual disease

HGSC

EC

CCC

LGSC

Hazard

95.0% CI

n

 

Hazard

95.0% CI

n

 

Hazard

95.0% CI

n

 

Hazard

95.0% CI

n

 

Ratio

Lower

Upper

 

p value

Ratio

Lower

Upper

 

p va lue

Ratio

Lower

Upper

 

p value

Ratio

Lower

Upper

 

p value

None

   

206

reference

   

119

reference

   

93

reference

   

16

reference

< 1 cm

1.72

1.31

2.23

230

0.000

3.80

1.63

8.84

29

0.002

2.24

1.17

4.29

26

0.015

1.10

0.45

2.72

21

0.835

Suboptimal

2.90

2.28

3.70

347

0.000

15.03

5.72

39.47

10

0.000

8.30

4.38

15.76

17

0.000

2.40

1.08

5.36

27

0.033

Stage

 I

   

70

reference

   

140

reference

   

124

reference

   

13

reference

 II

1.25

0.77

2.03

136

0.376

1.91

0.80

4.61

73

0.147

2.36

1.32

4.24

54

0.004

1.32

0.29

5.91

7

0.719

 III

3.17

2.09

4.81

820

0.000

6.48

3.04

13.82

44

0.000

8.15

4.93

13.48

58

0.000

2.73

0.98

7.63

68

0.056

 IV

4.61

2.93

7.26

120

0.000

NA

NA

NA

5

NA

19.35

7.57

49.43

7

0.000

7.11

1.87

27.00

6

0.004

  1. Bold values highlights the statistically significant difference with the reference category
  2. NA non applicable number of cases too low, n number of patients with follow-up, HR Hazard ratio, EOC epithelial ovarian cancer, CI confidence interval, HGSC High-Grade Serous Carcinoma, EC Endometrioid Carcinoma